Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Type 2 Diabetes Mellitus (T2DM) Clinical Trial

Official title:

Dapagliflozin Effect on Erythropoiesis and Physical Fitness in Patients With Type 2 Diabetes - a Randomized, Partly Double-blinded, Controlled, Three Armed, Parallel Group, Exploratory Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03423355
• Other study ID #: DapaFIT
• Status: Withdrawn
• Phase: Phase 4
• Start date: September 2021
• Est. completion date: December 2023

Study information

• Verified date: July 2021
• Source: University Hospital Tuebingen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study

Description:

Many patients with diabetes present with hyperglycemia, hypertension, hypercholesterolemia and excess weight, which are associated with micro- and macrovascular complications. Therapies to alleviate the burden of these complications have traditionally focused on reducing glycemia and optimizing blood pressure and cholesterol concentration. However, despite the various available treatment options to improve glycemic control, many patients do not reach treatment and lifestyle targets, such as improving physical fitness. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the proximal tubule reabsorption of filtered glucose, thereby causing glucosuria and decreasing plasma glucose concentrations. When large quantities of glucose are pharmacologically forced into urinary excretion, whole-body metabolism undergoes adaptive changes, involving glucose fluxes, hormonal responses, fuel selection, and energy expenditure. SGLT2 inhibitors have been proven to be superior to conventional therapy by reducing cardiovascular mortality in patients with cardiovascular diseases (CVD). Many of the explained mechanisms contribute to this effect, and other, still unknown factors, need to be identified.

In the present study, patients suffering from T2DM and hypertension will be treated with Dapagliflozin, an SGLT2 inhibitor, or matching Placebo, or HCT as reference drug with a diuretic and anti-hypertensive effect.

There is evidence that SGLT2 inhibition positively affects the erythropoietin-RBC axis. By this mechanism, Dapagliflozin improves oxygen supply to tissues, an effect which can explain the positive cardiovascular (CV) outcome data of Dapagliflozin in recent registry data. The aim of the present study is to provide clinical endpoints related to this effect. Specifically, the effect of Dapagliflozin on erythropoietin, reticulocytes, and HIF related factors will be studied and related to physical fitness before and after treatment with Dapagliflozin. Providing evidence for an improvement in physical fitness and cardiac function by Dapagliflozin will be of great clinical benefit in patients with T2DM, since a large number of these patients have reduced physical activity and heart failure. The increasing effect of SGLT2 inhibitors on hematocrit was initially attributed to a relative hemoconcentration due to the diuretic effect elicited by the drug. However, studies comparing Dapagliflozin directly to diuretic treatment with HCT showed that the effect of Dapagliflozin was superior to diuretic treatment with HCT. Moreover, Dapagliflozin, and not HCT, also increased reticulocytes count and EPO concentrations [1]. Together, these data suggest that hemoconcentration is not mediating the effect of Dapagliflozin on hemopoiesis and that other mechanisms must contribute. Yet, reducing preload by diuretic properties may beneficially affect physical performance and may, thus, affect the secondary endpoint. Therefore, three treatments will be used in this study: Dapagliflozin and matching placebo, and HCT as reference treatment for the diuretic effect.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male or female patients aged between 40 and 70 years (including)

• Diagnosis of type 2 diabetes mellitus (T2DM) with HbA1c between 7.1 10.0% (including)

• Stable treatment of type 2 diabetes, except with SGLT2-Inhibitors over the last 4 weeks

• Body mass index (BMI) between 25 kg/m2 and 35 kg/m2 (including)

• Blood pressure > 130/80 mmHg but 170/95 mmHg at maximum

• Ability to perform spiroergometry

• Ability to understand and follow study-related instructions

• Negative pregnancy test

• Patients who are receiving the following medications must be on a stable treatment regimen for at least 2 months prior to the screening visit (V0): antihypertensive agents, thyroid replacement therapy, antidepressant agents

Exclusion Criteria:

• Diagnosis of Type 1 diabetes

• History of diabetic ketoacidosis, hyperosmolar coma or corticosteroid-induced T2DM

• Repeated episodes of severe hypoglycaemia within the last 3 months prior to Screening

• Patients with significant thyroid disease

• Intention to change physical activity within the next 8 weeks

• Clinically significant cardiovascular disease (CVD) or procedure within 3 months prior to enrollment or expected to require coronary revascularization procedure

• Presence of history of severe congestive heart failure (NYHA III and IV), pace maker or aortic stenosis (AS) > II

• eGFR (as calculated by the MDRD equation) < 60 ml/min/1.73 m2

• Unstable or rapidly progressing renal disease or anuria

• Concomitant medication with loop diuretics

• Any previous exposure to dapagliflozin or any other SGLT2-Inhibitor, or HCT within last 3 months prior to Screening

• Triglyceride concentrations = 700 mg/dL (= 7.98 mmol/L) at the Screening visit (V0)

• History or presence of inflammatory bowel disease or other severe gastrointestinal diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis

• History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded

• • Significant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN) and/or total bilirubin (TB) > 2 mg/dL (> 34.2 µmol/L) (patients with TB > 2 mg/dL [> 34.2 µmol/L] and documented Gilbert's syndrome will be allowed to participate)

• Known human immunodeficiency virus (HIV) infection

• History of organ transplantation

• Malignancy (with the exception of basal and squamous cell carcinoma of the skin) within 5 years prior to the Screening visit (V1)

• • Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration < 12.0 g/dL) or any other condition known to interfere with the HbA1c methodology

• Patients who have donated blood or had a significant blood loss within 2 months of first dose of study medication or is planning to donate blood during the study

• Patients who have donated plasma within 7 days prior to first dose of study medication

• Systemic corticosteroids within 3 months prior to the Screening visit (V0) known to have a high rate of systemic absorption

• History of chronic obstructive pulmonary disease (COPD) or asthma

• Disabilities contraindicating spiroergometry

• Alcohol consumption > 20 g/day for women or > 30 g/day for men

• History of hypersensitivity to any of the study drugs or their ingredients

• Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI´s

• Addiction or other diseases that preclude the patient from appropriately assessing the nature and scope as well as possible consequences of the clinical study

• Pregnant or breastfeeding women

• Subject (male or female) is not willing to use highly effective contraceptive methods during treatment and for 14 days (male or female) after the end of treatment (highly effective methods are defined as: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.

• Participation in other clinical trials

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus (T2DM)

Intervention

Drug:
• Dapagliflozin (Forxiga®)
10mg p.o. daily
• Hydrochlorothiazide 25 mg
25mg p.o. daily
• Placebo matching Dapagliflozin
Placebo matching Dapagliflozin p.o. daily

Locations

Country	Name	City	State
Germany	University Hospital Tuebingen, Otfried-Mueller Str. 10	Tuebingen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in blood EPO levels	The primary objective is to investigate the change in erythropoietin (EPO) levels after 2 weeks of treatment with dapagliflozin in comparison to treatment with placebo.	2 weeks of treatment
Secondary	Change in physical fitness	Change in physical fitness between baseline and EoT as assessed by spiroergometry (VO2max, heart rate and blood pressure) with dapagliflozin in comparison to treatment with placebo	4 weeks of treatment
Secondary	Change in reticulocyte concentration, hematocrit and red blood cells	Change in reticulocyte concentration, hematocrit and red blood cells between baseline and after 2 and 4 weeks of treatment with dapagliflozin in comparison to treatment with placebo	baseline, 2 weeks and 4 weeks of treatment
Secondary	Change in hepcidin	Change in hepcidin between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in blood EPO levels	Change in blood EPO levels between baseline and EoT (comparison dapagliflozin vs HCT vs placebo)	baseline, 4 weeks of treatment
Secondary	Change in iron status (Fe)	Change in iron status between baseline and EoT as measured by Fe with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in iron status (Ferritin)	Change in iron status between baseline and EoT as measured by ferritin with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in iron status (Transferrin)	Change in iron status between baseline and EoT as measured by transferrin with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in catecholamine (adrenalin)	Change in adrenalin concentrations between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in catecholamine (noradrenalin)	Change in noradrenalin concentrations between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in catecholamine (metabolites metanephrine)	Change in metabolites metanephrine concentrations between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in catecholamine (normetanephrine)	Change in normetanephrine concentrations between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change in steroid hormone	Change in steroid hormone concentrations between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change of ejection fraction	Change of ejection fraction measured by echocardiography, between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment
Secondary	Change of diastolic function parameters	Change of diastolic function parameters measured by echocardiography, between baseline and EoT with dapagliflozin in comparison to treatment with placebo	baseline and 4 weeks of treatment